Nina and Lance join us again to continue our discussion and share predictions on Mesoblast's FDA ruling
The bulk of the chat was around Mesoblast's pending FDA decision for Ryoncil, their pediatric graft versus host disease therapy.
The panel took it to a vote on will it be approved or rejected. Listen and find out how the panel judged it. and of course you can see the widely reported outcome in various news outlets.
DISCLAIMER: opinions expressed are solely the interviewee’s own and do not express the views or opinions of their respective employers
Register for FREE for Phacilitate's next member event! Advanced Therapies Connect will take place on the 26-27 January 2021 and will be 100% virtual!
https://www.advancedtherapiesconnect.com/
Lance's link to Mass Bio Ed https://www.massbioed.org
Dark Horse are recruiting! https://darkhorseconsultinggroup.com/careers
And so is Nina's team at MilliporeSigma! https://www.merckgroup.com/en/careers.html
Finally, if you’re not already, don’t forget to sign-up as a Phacilitate member, it’s FREE! Every fortnight you’ll get the latest market intelligence, new ideas and exclusive event offers straight to your inbox.
Join a community with the same goal; to help advance a new standard in healthcare. https://www.phacilitate.co.uk/membership
Enjoy and, as always, please share your feedback.
You can also subscribe to the audio-only version, wherever you get your podcasts:
![[Q&A] Expanding Capacity and Talent in the Cell and Gene Therapy Industry (38807)](https://www.phacilitate.co.uk/sites/default/files/styles/thumbnail/public/sidebar_editor_pick/corporate_work_blog_banner_12.png?itok=zBvgIw1c)
